Key result
One-year mortality reaches ~5% post-ICD in HFrEF, predicted by clinical and biomarker risk factors.
Why the study?
Risk factors associated with mortality within one year following ICD implantation in HFrEF patients were not well defined.
Cohort (n=1,107)
No
May inform post-ICD risk stratification in HFrEF; hypothesis-generating and should not yet alter selection criteria.
Implantable cardioverter defibrillators (ICD) are recommended in heart failure with reduced ejection fraction (HFrEF) patients to reduce arrhythmic deaths. This study aimed to identify risk factors associated with mortality within one-year following the ICD. The data from our hospital's electronic database system was extracted for patients who were implanted ICD secondary to HFrEF between 2009 and 2019. Overall, 1107 patients were included in the present analysis. Mortality rate at one-year following the device implantation was 4.7%. In multivariate analysis; age, atrial fibrillation, New York Heart Association classification >2, blood urea nitrogen, pro-brain natriuretic peptide and albumin independently predicted one year mortality.
No takes yet. Share an insight, caveat, or question.
Çinier et al. (2022) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=1,107). Risk factors for early mortality (age, atrial fibrillation, NYHA >2, BUN, pro-BNP, albumin) vs. Absence of risk factors was evaluated on One-year mortality. In patients with HFrEF receiving an ICD, the one-year mortality rate was 4.7%, with older age, atrial fibrillation, NYHA class >2, elevated BUN and pro-BNP, and reduced albumin independently predicting early death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: